ParkinsonCanadaV1, PascalFrancis, Checkpoint, bibRecord, 000815

Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary

Identifieur interne : 000815 ( PascalFrancis/Checkpoint ); précédent : 000814; suivant : 000816

Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary

Auteurs : Deniz Kirik [Suède] ; Anders Björklund [Suède] ; Ivar Mendez [Canada] ; Rosario Sanchez-Pernaute [États-Unis] ; Oliver Cooper [États-Unis] ; Angel Vinuela [États-Unis] ; Daniela Ferrari [États-Unis] ; Lars Björklund [États-Unis] ; Alain Dagher [Canada] ; Ole Isacson [États-Unis]

Source :

Brain [ 0006-8950 ] ; 2005.

RBID : Pascal:05-0329433

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Analyse fonctionnelle, Dopamine, Locus niger, Homme, Transplantation, Neurone.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Dopamine, Functional analysis, Human, Locus niger, Nervous system diseases, Neuron, Parkinson disease, Transplantation.

Abstract

We report the first post-mortem analysis of two patients with Parkinson's disease who received fetal midbrain transplants as a cell suspension in the striatum, and in one case also in the substantia nigra. These patients had a favourable clinical evolution and positive ¹⁸F-fluorodopa PET scans and did not develop motor complications. The surviving transplanted dopamine neurons were positively identified with phenotypic markers of normal control human substantia nigra (n = 3), such as tyrosine hydroxylase, G-protein-coupled inward rectifying current potassium channel type 2 (Girk2) and calbindin. The grafts restored the cell type that provides specific dopaminergic innervation to the most affected striatal regions in the parkinsonian brain. Such transplants were able to densely reinnervate the host putamen with new dopamine fibres. The patients received only 6 months of standard immune suppression, yet by post-mortem analysis 3-4 years after surgery the transplants appeared only mildly immunogenic to the host brain, by analysis of microglial CD45 and CD68 markers. This study demonstrates that, using these methods, dopamine neuronal replacement cell therapy can be beneficial for patients with advanced disease, and that changing technical approaches could have a favourable impact on efficacy and adverse events following neural transplantation.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000900
to stream PascalFrancis, to step Curation: 000423

Links to Exploration step

Pascal:05-0329433

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary</title>
<author><name sortKey="Kirik, Deniz" sort="Kirik, Deniz" uniqKey="Kirik D" first="Deniz" last="Kirik">Deniz Kirik</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Wallenberg Neuroscience Center Department of Experimental Medical Science Lund University, BMC A11</s1>
<s2>22466, Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>22466, Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bjorklund, Anders" sort="Bjorklund, Anders" uniqKey="Bjorklund A" first="Anders" last="Björklund">Anders Björklund</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Wallenberg Neuroscience Center Department of Experimental Medical Science Lund University, BMC A11</s1>
<s2>22466, Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>22466, Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mendez, Ivar" sort="Mendez, Ivar" uniqKey="Mendez I" first="Ivar" last="Mendez">Ivar Mendez</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Dalhousie University and Queen Elizabeth II Health Science Center, Division of Neurosurgery and Neuroscience</s1>
<s2>Halifax</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sanchez Pernaute, Rosario" sort="Sanchez Pernaute, Rosario" uniqKey="Sanchez Pernaute R" first="Rosario" last="Sanchez-Pernaute">Rosario Sanchez-Pernaute</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cooper, Oliver" sort="Cooper, Oliver" uniqKey="Cooper O" first="Oliver" last="Cooper">Oliver Cooper</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vinuela, Angel" sort="Vinuela, Angel" uniqKey="Vinuela A" first="Angel" last="Vinuela">Angel Vinuela</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferrari, Daniela" sort="Ferrari, Daniela" uniqKey="Ferrari D" first="Daniela" last="Ferrari">Daniela Ferrari</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bjorklund, Lars" sort="Bjorklund, Lars" uniqKey="Bjorklund L" first="Lars" last="Björklund">Lars Björklund</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dagher, Alain" sort="Dagher, Alain" uniqKey="Dagher A" first="Alain" last="Dagher">Alain Dagher</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>McGill University and Montreal Neurological Institute, McConnel Brain Imaging Centre</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Isacson, Ole" sort="Isacson, Ole" uniqKey="Isacson O" first="Ole" last="Isacson">Ole Isacson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0329433</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0329433 INIST</idno>
<idno type="RBID">Pascal:05-0329433</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000900</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000423</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000815</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000815</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary</title>
<author><name sortKey="Kirik, Deniz" sort="Kirik, Deniz" uniqKey="Kirik D" first="Deniz" last="Kirik">Deniz Kirik</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Wallenberg Neuroscience Center Department of Experimental Medical Science Lund University, BMC A11</s1>
<s2>22466, Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>22466, Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bjorklund, Anders" sort="Bjorklund, Anders" uniqKey="Bjorklund A" first="Anders" last="Björklund">Anders Björklund</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Wallenberg Neuroscience Center Department of Experimental Medical Science Lund University, BMC A11</s1>
<s2>22466, Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<wicri:noRegion>22466, Lund</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mendez, Ivar" sort="Mendez, Ivar" uniqKey="Mendez I" first="Ivar" last="Mendez">Ivar Mendez</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Dalhousie University and Queen Elizabeth II Health Science Center, Division of Neurosurgery and Neuroscience</s1>
<s2>Halifax</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Halifax</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sanchez Pernaute, Rosario" sort="Sanchez Pernaute, Rosario" uniqKey="Sanchez Pernaute R" first="Rosario" last="Sanchez-Pernaute">Rosario Sanchez-Pernaute</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cooper, Oliver" sort="Cooper, Oliver" uniqKey="Cooper O" first="Oliver" last="Cooper">Oliver Cooper</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vinuela, Angel" sort="Vinuela, Angel" uniqKey="Vinuela A" first="Angel" last="Vinuela">Angel Vinuela</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferrari, Daniela" sort="Ferrari, Daniela" uniqKey="Ferrari D" first="Daniela" last="Ferrari">Daniela Ferrari</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bjorklund, Lars" sort="Bjorklund, Lars" uniqKey="Bjorklund L" first="Lars" last="Björklund">Lars Björklund</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dagher, Alain" sort="Dagher, Alain" uniqKey="Dagher A" first="Alain" last="Dagher">Alain Dagher</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>McGill University and Montreal Neurological Institute, McConnel Brain Imaging Centre</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Isacson, Ole" sort="Isacson, Ole" uniqKey="Isacson O" first="Ole" last="Isacson">Ole Isacson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Belmont, MA</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Brain</title>
<title level="j" type="abbreviated">Brain</title>
<idno type="ISSN">0006-8950</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain</title>
<title level="j" type="abbreviated">Brain</title>
<idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Functional analysis</term>
<term>Human</term>
<term>Locus niger</term>
<term>Nervous system diseases</term>
<term>Neuron</term>
<term>Parkinson disease</term>
<term>Transplantation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Analyse fonctionnelle</term>
<term>Dopamine</term>
<term>Locus niger</term>
<term>Homme</term>
<term>Transplantation</term>
<term>Neurone</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report the first post-mortem analysis of two patients with Parkinson's disease who received fetal midbrain transplants as a cell suspension in the striatum, and in one case also in the substantia nigra. These patients had a favourable clinical evolution and positive <sup>18</sup>
F-fluorodopa PET scans and did not develop motor complications. The surviving transplanted dopamine neurons were positively identified with phenotypic markers of normal control human substantia nigra (n = 3), such as tyrosine hydroxylase, G-protein-coupled inward rectifying current potassium channel type 2 (Girk2) and calbindin. The grafts restored the cell type that provides specific dopaminergic innervation to the most affected striatal regions in the parkinsonian brain. Such transplants were able to densely reinnervate the host putamen with new dopamine fibres. The patients received only 6 months of standard immune suppression, yet by post-mortem analysis 3-4 years after surgery the transplants appeared only mildly immunogenic to the host brain, by analysis of microglial CD45 and CD68 markers. This study demonstrates that, using these methods, dopamine neuronal replacement cell therapy can be beneficial for patients with advanced disease, and that changing technical approaches could have a favourable impact on efficacy and adverse events following neural transplantation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8950</s0>
</fA01>
<fA03 i2="1"><s0>Brain</s0>
</fA03>
<fA05><s2>128</s2>
</fA05>
<fA06><s3>p.7</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KIRIK (Deniz)</s1>
<s9>comment.</s9>
</fA11>
<fA11 i1="02" i2="1"><s1>BJÖRKLUND (Anders)</s1>
<s9>comment.</s9>
</fA11>
<fA11 i1="03" i2="1"><s1>MENDEZ (Ivar)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SANCHEZ-PERNAUTE (Rosario)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>COOPER (Oliver)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>VINUELA (Angel)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FERRARI (Daniela)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BJÖRKLUND (Lars)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DAGHER (Alain)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ISACSON (Ole)</s1>
</fA11>
<fA14 i1="01"><s1>Wallenberg Neuroscience Center Department of Experimental Medical Science Lund University, BMC A11</s1>
<s2>22466, Lund</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Dalhousie University and Queen Elizabeth II Health Science Center, Division of Neurosurgery and Neuroscience</s1>
<s2>Halifax</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence</s1>
<s2>Belmont, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>McGill University and Montreal Neurological Institute, McConnel Brain Imaging Centre</s1>
<s2>Montreal</s2>
<s3>CAN</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s2>1478-1479,1498-1510 [15 p.]</s2>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>998</s2>
<s5>354000138025910020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>dissem.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0329433</s0>
</fA47>
<fA60><s1>P</s1>
<s3>AR</s3>
<s3>CT</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We report the first post-mortem analysis of two patients with Parkinson's disease who received fetal midbrain transplants as a cell suspension in the striatum, and in one case also in the substantia nigra. These patients had a favourable clinical evolution and positive <sup>18</sup>
F-fluorodopa PET scans and did not develop motor complications. The surviving transplanted dopamine neurons were positively identified with phenotypic markers of normal control human substantia nigra (n = 3), such as tyrosine hydroxylase, G-protein-coupled inward rectifying current potassium channel type 2 (Girk2) and calbindin. The grafts restored the cell type that provides specific dopaminergic innervation to the most affected striatal regions in the parkinsonian brain. Such transplants were able to densely reinnervate the host putamen with new dopamine fibres. The patients received only 6 months of standard immune suppression, yet by post-mortem analysis 3-4 years after surgery the transplants appeared only mildly immunogenic to the host brain, by analysis of microglial CD45 and CD68 markers. This study demonstrates that, using these methods, dopamine neuronal replacement cell therapy can be beneficial for patients with advanced disease, and that changing technical approaches could have a favourable impact on efficacy and adverse events following neural transplantation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A25L</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Analyse fonctionnelle</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Functional analysis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Análisis funcional</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Transplantation</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Transplantation</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Trasplantación</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Neurone</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Neuron</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Neurona</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>234</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Canada</li>
<li>Suède</li>
<li>États-Unis</li>
</country>
<region><li>Québec</li>
</region>
<settlement><li>Montréal</li>
</settlement>
</list>
<tree><country name="Suède"><noRegion><name sortKey="Kirik, Deniz" sort="Kirik, Deniz" uniqKey="Kirik D" first="Deniz" last="Kirik">Deniz Kirik</name>
</noRegion>
<name sortKey="Bjorklund, Anders" sort="Bjorklund, Anders" uniqKey="Bjorklund A" first="Anders" last="Björklund">Anders Björklund</name>
</country>
<country name="Canada"><noRegion><name sortKey="Mendez, Ivar" sort="Mendez, Ivar" uniqKey="Mendez I" first="Ivar" last="Mendez">Ivar Mendez</name>
</noRegion>
<name sortKey="Dagher, Alain" sort="Dagher, Alain" uniqKey="Dagher A" first="Alain" last="Dagher">Alain Dagher</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Sanchez Pernaute, Rosario" sort="Sanchez Pernaute, Rosario" uniqKey="Sanchez Pernaute R" first="Rosario" last="Sanchez-Pernaute">Rosario Sanchez-Pernaute</name>
</noRegion>
<name sortKey="Bjorklund, Lars" sort="Bjorklund, Lars" uniqKey="Bjorklund L" first="Lars" last="Björklund">Lars Björklund</name>
<name sortKey="Cooper, Oliver" sort="Cooper, Oliver" uniqKey="Cooper O" first="Oliver" last="Cooper">Oliver Cooper</name>
<name sortKey="Ferrari, Daniela" sort="Ferrari, Daniela" uniqKey="Ferrari D" first="Daniela" last="Ferrari">Daniela Ferrari</name>
<name sortKey="Isacson, Ole" sort="Isacson, Ole" uniqKey="Isacson O" first="Ole" last="Isacson">Ole Isacson</name>
<name sortKey="Vinuela, Angel" sort="Vinuela, Angel" uniqKey="Vinuela A" first="Angel" last="Vinuela">Angel Vinuela</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000815 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000815 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:05-0329433
   |texte=   Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary

Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri